U.S. Gene Editing Market Report 2022: Emergence Of Novel Gen...| MENAFN.COM

Monday, 05 December 2022 06:01 GMT

U.S. Gene Editing Market Report 2022: Emergence Of Novel Gene Editing Tools Presents Opportunities'


(MENAFN- PR Newswire)

DUBLIN, Nov. 25, 2022 /PRNewswire/ --
The 'u.s. gene editing market - industry outlook & forecast 2022-2027' report has been added to
ResearchAndMarkets.com's
offering.

The U.S. gene editing market is expected to grow at a CAGR of 21.13% during 2022-2027. MARKET INSIGHTS Growth in the gene editing market is fueled by increasing demand for synthetic genes in the U.S. Genomics can be used to identify genetic abnormalities in humans, drug discovery, agriculture, veterinary medicine, and forensics. Gene editing requires tools and techniques that make unique changes to the DNA sequence of an organism's genes, fundamentally altering the genetic blueprint. Unlike genetic engineering, which randomly incorporates genetic material into the host genome, gene editing aims to make changes at specific target locations.Genome editing technology is a technique for target gene modification that allows the knockout and addition of specific fragments of DNA. This technique is widely used in biomedical research, clinics, and agriculture. A growing preference for personalized medicine, rare disease treatment research, rising R&D spending and growth in the pharmaceutical and biotech industries, rapid advances in sequencing and genome editing technologies, and increasing use of products derived from genetically modified organisms. These are some of the factors that are boosting the growth of the U.S. gene editing market.

Market Dynamics

Market Opportunities & Trends

  • Emergence of Novel Gene Editing Tools
  • Use of Gene Editing in Personalized Medicine
  • Increased Pharma/Biotech, Venture Capital & Government Funding for Gene Editing Projects
  • High Number of Gene Editing-Based Investigational Drugs

Market Growth Enablers

  • Advances in Genome Editing Platforms
  • Large Target Population With Rare Genetic Disorders
  • Demand for Gene Editing in Drug Discovery & Development
  • Diverse Applications of Gene Editing

Market Restraints

  • High Cost & Time Involved in Gene Editing
  • Technical Challenges Related to Gene Editing
  • Ethical & Safety Concerns Associated With Gene Editing

SEGMENTATIONS Segmentation by Products

  • Reagents & Consumables
  • Equipment & Software
  • Services

Segmentation by Technology

  • CRISPER
  • TALEN
  • ZFN
  • Others

Segmentation by Application

  • Drug Discovery & Development (DDD)
  • Animal Gene Editing
  • Plant Gene Editing
  • Others

Segmentation by End User

  • Pharma & Biotech Companies (PBC)
  • Academic & Research Institutes (ARI)
  • Animal & Plant Biotech Companies (APBC)
  • CROs/CDMOs

Key Vendors

  • Agilent Technologies
  • Creative Biogene
  • Genscript
  • Merck KGaA
  • Thermo Fisher Scientific
  • Takara Bio

Other Prominent Vendors

  • Arbor Biotechnologies
  • Beam Therapeutics
  • Bluebird Bio
  • Cellectis
  • Caribou Biosciences
  • Charles River Laboratories
  • CRISPR Therapeutics
  • HERA Biolabs
  • Integrated DNA Technologies
  • Lonza
  • New England Biolabs
  • OriGene Technologies
  • Synthego
  • Tecan
  • PerkinElmer
  • Precision BioSciences
  • Intellia Therapeutics
  • Pairwise
  • Sangamo Therapeutics
  • Recombinetics
  • Synbio Technologies

Key Topics Covered: 1 Research Methodology 2 Research Objectives 3 Research Process 4 Scope & Coverage 5 Report Assumptions & Caveats 6 Market at a Glance 7 Premium Insights 8 Introduction 9 Market Opportunities & Trends 10 Market Growth Enablers 11 Market Restraints 12 Market Landscape 13 Product 14 Technology 15 Application 16 End-User 17 Competitive Landscape 18 Key Company Profiles 19 Other Prominent Vendors 20 Report Summary 21 Quantitative Summary 22 Appendix Companies Mentioned

  • Agilent Technologies
  • Creative Biogene
  • Genscript
  • Merck KGaA
  • Thermo Fisher Scientific
  • Takara Bio
  • Arbor Biotechnologies
  • Beam Therapeutics
  • Bluebird Bio
  • Cellectis
  • Caribou Biosciences
  • Charles River Laboratories
  • CRISPR Therapeutics
  • HERA Biolabs
  • Integrated DNA Technologies
  • Lonza
  • New England Biolabs
  • OriGene Technologies
  • Synthego
  • Tecan
  • PerkinElmer
  • Precision BioSciences
  • Intellia Therapeutics
  • Pairwise
  • Sangamo Therapeutics
  • Recombinetics
  • Synbio Technologies

For more information about this report visit

Media Contact:

Research and MarketsLaura Wood, Senior Manager[email protected]

For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716

Logo:

SOURCE Research and Markets

MENAFN25112022003732001241ID1105233504


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.